Live Breaking News & Updates on ஃபியோர்ட் முயற்சிகள்
Stay updated with breaking news from ஃபியோர்ட் முயற்சிகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adagio Medical Reports 85% Freedom from AF at 12 Months After a Single Ablation Procedure in Patients with Persistent Atrial Fibrillation and Presents Recent Developments of Pulsed Field Cryoablation Technology finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
GenesisCare and PreludeDx™ Form Precision Medicine Global Partnership prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
GenesisCare and PreludeDx™ Form Precision Medicine Global Partnership apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
(1) LAGUNA HILLS, Calif., July 7, 2021 /PRNewswire/ Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), today announced successful first-in-human use of ultra-low temperature cryoablation (ULTC) for the treatment of monomorphic VT. The two-hour mapping and ablation procedure was performed by Dr. Tom De Potter, MD, Associate Director, Cardiovascular Center Department of Cardiology, Electrophysiology Section at the Cardiovascular Center OLV Hospital, Aalst, Belgium. Procedural success was ascertained by the lack of the inducible arrhythmia after a set of ULTC lesions was delivered to isolate inferior-posterior ischemic scar in patient s left ventricle. No procedural complications were observed, and patient remained arrhythmia-free through the first 30 days of the follow-up. ....
/PRNewswire/ Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, presented data at the. ....